Growth Metrics

Oculis Holding AG (OCS) Return on Assets (2023 - 2026)

Quarterly Return on Assets rose 59.0% to 0.69% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.69% through Mar 2026, up 59.0% year-over-year, with the annual reading at 0.01% for FY2025, 0.0% changed from the prior year.

Oculis Holding AG's Return on Assets history spans 4 years, with the latest figure at 0.69% for Q1 2026.

  • Return on Assets came in at 0.69% for Q1 2026, up from 0.83% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.01% in Q1 2024 to a low of 1.65% in Q4 2024.
  • The 4-year median for Return on Assets is 0.83% (2025), against an average of 0.73%.
  • Year-over-year, Return on Assets plummeted -165bps in 2024 and then soared 82bps in 2025.
  • Oculis Holding AG's Return on Assets stood at 0.01% in 2023, then crashed by -23167bps to 1.65% in 2024, then skyrocketed by 50bps to 0.83% in 2025, then increased by 17bps to 0.69% in 2026.
  • Per Business Quant, the three most recent readings for OCS's Return on Assets are 0.69% (Q1 2026), 0.83% (Q4 2025), and 0.99% (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -0.01%
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 0.00%
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -0.01%
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 0.00%
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 0.00%
8 Evaxion A 65.12 Bn 65.10 Bn - 0.00%
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 0.00%
10 Oculis Holding AG 24.51 Bn 24.21 Bn - -0.69%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.69%
Dec 31, 2025 -0.83%
Sep 30, 2025 -0.99%
Jun 30, 2025 -1.05%
Mar 31, 2025 -1.28%
Dec 31, 2024 -1.65%
Sep 30, 2024 -1.56%
Jun 30, 2024 -0.01%
Mar 31, 2024 -0.01%
Dec 31, 2023 -0.01%
Sep 30, 2023 -0.01%